Retargeting T Cells for HER2-Positive Tumor Killing by a Bispecific Fv-Fc Antibody

Advances in bispecific biotherapeutics for the treatment of cancer

(2012) Chad May et al.   BIOCHEMICAL PHARMACOLOGY

Strategies for extended serum half-life of protein therapeutics

(2011) Roland E Kontermann   CURRENT OPINION IN BIOTECHNOLOGY

Introduction to current and future protein therapeutics: A protein engineering perspective

(2011) Paul J. Carter   EXPERIMENTAL CELL RESEARCH

Bispecific antibodies engage T cells for antitumor immunotherapy

(2011) Bryan D Choi et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Bispecific Antibodies for Cancer Immunotherapy

(2010) Dafne Müller et al.   BIODRUGS

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

(2010) Richard A Morgan et al.   MOLECULAR THERAPY

A Simple and Sensitive Method for Measuring Tumor-Specific T Cell Cytotoxicity

(2010) Xinping Fu et al.   PLoS One

Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties

(2010) G. Wozniak-Knopp et al.   PROTEIN ENGINEERING DESIGN & SELECTION

The Trifunctional Antibody Ertumaxomab Destroys Tumor Cells That Express Low Levels of Human Epidermal Growth Factor Receptor 2

(2009) M. Jager et al.   CANCER RESEARCH